Inhibition of filamentation can be used to treat disseminated candidiasis

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 10, 2006, Pages 3312-3316

  Saville, Stephen P ^a   Lazzell, Anna L ^a   Bryant, Alexander P ^b   Fretzen, Angelika ^b   Monreal, Alex ^b   Solberg, Erik O ^b   Monteagudo, Carlos ^c   Lopez Ribot, Jose L ^a   Milne, G Todd ^b  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b Microbia PE Inc   (United States)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; DOXYCYCLINE; FLUCONAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG TARGETING; DRUG WITHDRAWAL; FEMALE; FILAMENTATION; FUNGAL MORPHOLOGY; FUNGAL STRAIN; FUNGAL VIRULENCE; GENETIC ENGINEERING; IN VITRO STUDY; IN VIVO STUDY; LETHALITY; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SURVIVAL RATE;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DNA-BINDING PROTEINS; DOXYCYCLINE; FEMALE; GENE EXPRESSION REGULATION, FUNGAL; GENETIC ENGINEERING; HYPHAE; KIDNEY; MICE; MICE, INBRED BALB C; REPRESSOR PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; VIRULENCE;

EID: 33749513604     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00628-06     Document Type: Article

References (16)

1. Beck-Sague, C., W. R. Jarvis, et al. 1993. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J. Infect. Dis. 167:1247-1251.
2. Braun, B. R., and A. D. Johnson. 2000. TUP1, CPH1 and EFG1 make independent contributions to filamentation in Candida albicans. Genetics 155:57-67.
3. Braun, B. R., D. Kadosh, and A. D. Johnson. 2001. NRG1, a repressor of filamentous growth in C. albicans, is down-regulated during filament induction. EMBO J. 20:4753-4761.
4. Garey, K. W., M. Rege, M. P. Pai, D. E. Mingo, K. J. Suda, R. S. Turpin, and D. T. Bearden. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31.
5. Liu, H., J. Kohler, and G. R. Fink. 1994. Suppression of hyphal formation in Candida albicans by mutation of a STE12 homolog. Science 266:1723-1726.
6. Lo, H. J., J. R. Kohler, B. DiDomenico, D. Loebenberg, A. Cacciapuoti, and G. R. Fink. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell 90:939-949.
7. MacCallum, D. M., and F. C. Odds. 2004. Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection. Antimicrob. Agents Chemother. 48:4911-4914.
8. Morrell, M., V. J. Fraser, and M. H. Kollef. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49:3640-3645.
9. Murad, A. M., P. Leng, M. Straffon, J. Wishart, S. Macaskill, D. MacCallum, N. Schnell, D. Talibi, D. Marechal, F. Tekaia, C. d'Enfert, C. Gaillardin, F. C. Odds, and A. J. Brown. 2001. NRG1 represses yeast-hypha morphogenesis and hypha-specific gene expression in Candida albicans. EMBO J. 20:4742-4752.
10. Sanglard, D., and F. C. Odds. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85.
11. Saville, S. P., A. L. Lazzell, C. Monteagudo, and J. L. Lopez-Ribot. 2003. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot. Cell 2:1053-1060.
12. Stoldt, V. R., A. Sonneborn, C. E. Leuker, and J. F. Ernst. 1997. Efg1p, an essential regulator of morphogenesis of the human pathogen Candida albicans, is a member of a conserved class of bHLH proteins regulating morphogenetic processes in fungi. EMBO J. 16:1982-1991.
13. Toenjes, K. A., S. M. Munsee, A. S. Ibrahim, R. Jeffrey, J. E. Edwards, Jr., and D. I. Johnson. 2005. Small-molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans. Antimicrob. Agents Chemother. 49:963-972.
14. Viudes, A., J. Peman, E. Canton, P. Ubeda, J. L. Lopez-Ribot, and M. Gobernado. 2002. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur. J. Clin. Microbiol. Infect. Dis. 21:767-774.
15. Wey, S. B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1988. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch. Intern. Med. 148:2642-2645.
16. Wilson, L. S., C. M. Reyes, M. Stolpman, J. Speckman, K. Allen, and J. Beney. 2002. The direct cost and incidence of systemic fungal infections. Value Health 5:26-34.